JAC Advance Access published online on November 9, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki393
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra Majadahonda-Pozuelo Km 2. 28220 Majadahonda (Madrid), Spain
* To whom correspondence should be addressed. Objectives: Activities in vitro of six antifungal agents were tested against a collection of 317 Cryptococcus neoformans var. neoformans clinical isolates. Methods: The procedure described in document 7.1 by the European Committee on Antibiotic Susceptibility Testing with minor modifications was employed. Results: Amphotericin B, itraconazole, voriconazole and ravuconazole exhibited a potent activity with geometric mean (GM) MICs under 0.26 mg/L. The GM MIC of flucytosine was 7.33 mg/L and that of fluconazole was 4.16 mg/L. The rates of antifungal resistance were 5.3% for amphotericin B, 0.9% for voriconazole and 3.1% for ravuconazole. Fifteen point eight per cent of strains had itraconazole MICs Conclusions: The percentage of fluconazole susceptibility was significantly lower than that in other surveys. Cross-resistance to itraconazole was common (33.8%) but almost the whole collection was susceptible to voriconazole and ravuconazole. These results should be confirmed with prospective and population-based surveillance programmes.
Received July 26, 2005
Revised September 27, 2005
Accepted October 3, 2005
Brief report
Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans
Manuel Cuenca-Estrella, E-mail: mcuenca-estrella{at}isciii.es
![]()
Abstract
1 mg/L, and 46% of strains had flucytosine MICs
8 mg/L. Fluconazole susceptibility (MIC
8 mg/L) stood at 53.4%.![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. D. Cannon, E. Lamping, A. R. Holmes, K. Niimi, P. V. Baret, M. V. Keniya, K. Tanabe, M. Niimi, A. Goffeau, and B. C. Monk Efflux-Mediated Antifungal Drug Resistance Clin. Microbiol. Rev., April 1, 2009; 22(2): 291 - 321. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Pfaller, D. J. Diekema, D. L. Gibbs, V. A. Newell, H. Bijie, D. Dzierzanowska, N. N. Klimko, V. Letscher-Bru, M. Lisalova, K. Muehlethaler, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing J. Clin. Microbiol., January 1, 2009; 47(1): 117 - 123. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. T. Dias, F. E. Matsumoto, M. S. C. Melhem, E. G. da Silva, M. E. Auler, A. M. de Siqueira, and C. R. Paula Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates. J. Med. Microbiol., December 1, 2006; 55(Pt 12): 1693 - 1699. [Abstract] [Full Text] [PDF] |
||||


